Page 5 - Pharmaceutical Companies

Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared

Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 249 crore in the October-December period of previous fiscal. Net sales increased to Rs 2,459 crore in the quarter under review as against Rs 2,092 crore in the year-ago period, the company said in a regulatory filing. The company's board, which met on Wednesday, declared an interim dividend of Rs 14 (280 per cent) per share of Rs 5 each. On Wednesday, shares of the company ended 1.86 per cent down at Rs 1,557.50 apiece on the BSE.

WHO issues a 'medical product alert' for Marion Biotech cough syrup

The WHO has said Marion Biotech had not provided guarantees to them on the safety and quality of these products

Sun Pharmaceuticals launches drug for advanced breast cancer patients

Sun Pharmaceutical on Wednesday launched a novel anti-cancer drug Palbociclib under the brand name of Palenotm for patients with advanced breast cancer.

Around 21 API projects come up under the PLI scheme, shows data

These units have an installed capacity of 33,895 tonnes

Granules India ties up with Greenko Group for 'green' pharma zones

As a part of the partnership, Granules and Greenko ZeroC will develop and promote state-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

Hyderabad-based drug major Hetero prices Paxlovid generic at $60 per course

Generic version of Pfizer's Covid antiviral treatment would be exported for $70

Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic Fulvestrant injection used in treatment of breast cancer. The approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA), Fulvestrant injection of strength 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, the company said in a statement. The approved injection is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, of AstraZeneca Pharmaceuticals LP, it added. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of breast cancer, the company said. For 12 months ended September 2022, Fulvestrant injection, 250 mg/5 mL, had an estimated market size of USD 71 million, the company said citing IQVIA data.

Pharma exports likely to touch all-time high of $27 bn in FY23 riding on EU

Better figure expected despite global headwinds; India has so far exported pharma products worth $16.57 bn during April-November this year

Lupin set to gain market share in US flu season; shares up 6% in 2 sessions

The stock has underperformed peers and the benchmark over the past year

Maiden Pharma cough syrup row: Gambian Parliament seeks legal action

WHO, however, said samples tested in Ghana and Switzerland were found to be contaminated

Gambia panel seeks Indian manufacturer's prosecution for cough syrup deaths

A parliamentary committee in The Gambia has recommended prosecution of an Indian manufacturer of cough syrups suspected of causing the deaths of at least 70 children in the West African country

Indian pharma sector set for 'volume to value leadership' journey in 2023

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership

USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant

The US health regulator has pulled up drug maker Glenmark Pharmaceuticals for manufacturing lapses, including failure to establish required laboratory control mechanisms, at its Goa-based manufacturing plant. In a warning letter addressed to Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha, the US Food and Drug Administration (USFDA) pointed out various lapses at the company's Bardez-based facility in Goa, which produces drug formulations. The US Health regulator noted that the "warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals". It further said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated..." The USFDA inspected the manufacturing facility from May 12, 2022, to May 20, 2022. In the warning letter, the US health regulator pointed out the company's failure "to ...

Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

The USFDA had imposed an import ban on the Halol plant in December 2015 too

Flu season starts, but demand for cough-cold meds remains weak

Impact in US among the worst in the past 10 years

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Indian pharma exports rise by 4.22% to $14.57 bn during April-Oct

Pharmaceutical exports from India registered a growth of 4.22 per cent to reach USD 14.57 billion during the April-October period despite a negative trend last month, according to a senior official of an export promotion body under Government of India. Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India (Pharmexcil) which is an organisation under the Ministry of Commerce, said he was hopeful of ending the current fiscal at around USD 27 billion as against USD 24.62 billion during the last financial year. "There was a dip (-0.32 per cent) in July and (-5.45 per cent) and there was 8.47 per cent positive growth in September. I am optimistic that it will be revived in the coming months and may touch USD 27 billion at the end of the fiscal," Bhaskar told PTI. During the same period last fiscal, the exports fetched USD 13.98 billion. USA, Canada and Mexico (NAFTA countries), Europe and Africa account for 67.5 per cent (nearly USD 5 billion) of the total